Graphite Bio Insider Porteus Holds 3.5M Shares

TL;DR

**Insider Matthew Porteus still holds 3.5M shares of Graphite Bio, showing strong conviction.**

AI Summary

Matthew Porteus, an insider at Graphite Bio, Inc., filed an amended SC 13G/A on February 5, 2024, disclosing his beneficial ownership of 3,548,529 shares of the company's Common Stock as of December 31, 2023. This filing indicates a change in his reported holdings, providing an updated snapshot of his significant stake in the gene-editing biotechnology company. For investors, this matters because it shows a key insider's continued substantial investment, which can be interpreted as a sign of confidence in the company's future, especially given Graphite Bio's focus on developing treatments for serious genetic diseases.

Why It Matters

This filing updates Matthew Porteus's beneficial ownership, signaling his continued significant stake in Graphite Bio, which can influence investor perception of the company's stability and future prospects.

Risk Assessment

Risk Level: low — This filing is an update on an insider's holdings, which generally carries low direct risk to the company or its stock price.

Analyst Insight

Investors should note that a key insider, Matthew Porteus, maintains a substantial stake in Graphite Bio, which could be a positive signal of long-term confidence, but this filing alone doesn't indicate any immediate buying or selling activity.

Key Numbers

• 3,548,529 — Shares Beneficially Owned (Represents Matthew Porteus's total beneficial ownership in Graphite Bio, Inc. as of December 31, 2023.)
• 0 — Shared Voting Power (Indicates Matthew Porteus has no shared voting power over the reported shares.)
• 0 — Shared Dispositive Power (Indicates Matthew Porteus has no shared dispositive power over the reported shares.)

Key Players & Entities

• Matthew Porteus (person) — Reporting Person, insider at Graphite Bio, Inc.
• Graphite Bio, Inc. (company) — Issuer of the securities
• 3,548,529 shares (dollar_amount) — Number of shares beneficially owned by Matthew Porteus
• December 31, 2023 (date) — Date of event requiring the filing

Forward-Looking Statements

• Matthew Porteus will maintain a significant ownership stake in Graphite Bio, Inc. (Matthew Porteus) — high confidence, target: Next 12 months

FAQ

Key Financial Figures

• $0.00001 — me of Issuer) Common Stock, Par Value $0.00001 Per Share (Title of Class of Securiti

Filing Documents

• d710000dsc13ga.htm (SC 13G/A) — 42KB
• 0001193125-24-024106.txt ( ) — 44KB

(a)

Item 1(a). Name of Issuer: Graphite Bio, Inc. (the Issuer)

(b)

Item 1(b). Address of Issuers Principal Executive Offices: 611 Gateway Boulevard, Suite 120 South San Francisco, CA 94080

(a)

Item 2(a). Name of Person Filing: Matthew Porteus

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: c/o Graphite Bio, Inc. 611 Gateway Boulevard, Suite 120 South San Francisco, CA 94080

(c)

Item 2(c). Citizenship: United States

(d)

Item 2(d). Title of Class of Securities: Common Stock

(e)

Item 2(e). CUSIP Number: 38870X104 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a- 8). (e) An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). Not applicable. CUSIP No. 38870X104 13G/A Page 4 of 5 Pages Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,548,529 shares of Common Stock which consists of (i) 3,528,529 shares of Common Stock held directly by Matthew Porteus and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus. (b) Percent of class: 6.1% The foregoing percentage is calculated based on (i) 58,008,396 shares of Common Stock outstanding as of December 31, 2023 and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus, which have been added to the Common Stock reported as outstan

View Full Filing

View this SC 13G/A filing on SEC EDGAR